Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing novel sublingual drug delivery mechanisms for known drugs. Its lead product is a high-dose sublingual aspirin (informally called Instaprin) targeting acute myocardial infarction, stroke prevention, and pain management. The company completed a Phase I bioavailability clinical trial in July 2025 and plans to submit a 505(b)(2) NDA to the FDA in late 2026. It also has sublingual formulations of melatonin and other products in early development.
Q2 FY2026 — expected 2026-09-25
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001493152-26-013682 | EDGAR | 89K words |
| 2025-04-07 | 2024-12-31 | 0001641172-25-002917 | EDGAR | 75K words |
| 2024-03-11 | 2023-12-31 | 0001493152-24-009602 | EDGAR | 48K words |
| 2023-03-21 | 2022-12-31 | 0001410578-23-000316 | EDGAR | 42K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001493152-26-037819 | EDGAR | 37K words |
| 2025-11-14 | 2025-09-30 | 0001493152-25-022595 | EDGAR | 34K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023573 | EDGAR | 29K words |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010316 | EDGAR | 28K words |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045850 | EDGAR | 24K words |
| 2024-08-16 | 2024-06-30 | 0001493152-24-032815 | EDGAR | 22K words |
| 2024-06-05 | 2024-03-31 | 0001493152-24-022728 | EDGAR | 23K words |
| 2023-11-08 | 2023-09-30 | 0001493152-23-039795 | EDGAR | 19K words |
| 2023-08-08 | 2023-06-30 | 0001410578-23-001594 | EDGAR | 18K words |
| 2023-05-11 | 2023-03-31 | 0001410578-23-001031 | EDGAR | 17K words |
| 2022-11-10 | 2022-09-30 | 0001410578-22-003172 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001410578-22-002287 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-09 | 0001493152-26-041918 | EDGAR | 2K words |
| 2026-09-08 | 0001493152-26-041725 | EDGAR | 1K words |
| 2026-08-19 | 0001493152-26-039135 | EDGAR | 0K words |
| 2026-08-10 | 0001493152-26-036777 | EDGAR | 2K words |
| 2026-07-20 | 0001493152-26-033942 | EDGAR | 1K words |
| 2026-02-12 | 0001493152-26-006343 | EDGAR | 25K words |
| 2026-02-06 | 0001493152-26-005640 | EDGAR | 16K words |
| 2026-01-30 | 0001493152-26-004543 | EDGAR | 19K words |
| 2026-01-15 | 0001493152-26-002326 | EDGAR | 13K words |
| 2026-01-13 | 0001493152-26-002057 | EDGAR | 1K words |
83 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001847345 |
| Ticker | ASBP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | E9 |
| Website | https://www.aspirebiolabs.com |
| Listed | 2025-02-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ASBP (~200 tokens, structured JSON with cryptographic provenance)